Peri-operative immunotherapy, particularly anti-programmed cell death protein-1 therapy, combined with neoadjuvant chemotherapy has emerged as one of the standard-of-care options for resectable non-small cell lung cancer (NSCLC). We report the final analysis of RATIONALE-315, a randomized, double-blind, phase III trial evaluating the efficacy and safety of peri-operative tislelizumab plus neoadjuvant chemotherapy versus neoadjuvant chemotherapy alone in patients with resectable, stage…
Peri-operative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small cell lung cancer: final analysis of the randomized RATIONALE-315 trial
Annals of Oncology | | C. Wang, W. Wang, H. Liu, Q. Chen, C. Chen, L. Liu, P. Zhang, G. Zhao, F. Yang, G. Han, B. Yu, Y. Yang, H. Chen, J. Jiang, L. Tan, S. Xu, N. Mao, J. Hu, L. Zhang, Z. Zhang, B. Yao, S. Wang, S. Leaw, K. Naicker, W. Zheng, C. Yu, D. Yue, RATIONALE-315 investigators
Topics: lung-cancer, blood-cancer, immunotherapy, chemotherapy, clinical-trials